

Curriculum Vitae of
T. Joseph “Joey” Mattingly II, PharmD, MBA, PhD

Park City, Utah
Email: joey.mattingly@utah.edu

EDUCATION

University of Maryland, Baltimore Baltimore, Maryland Doctor of Philosophy, Pharmaceutical Health Services Research	August 2015 – May 2019
University of Kentucky College of Pharmacy Lexington, Kentucky Doctor of Pharmacy, Magna Cum Laude	August 2005 – May 2009
University of Kentucky Gatton College of Business and Economics Lexington, Kentucky Masters of Business Administration, Magna Cum Laude	August 2006 – May 2009

EMPLOYMENT

University of Utah College of Pharmacy

Director, Health Economics & Value Assessment, UHealth Strategy	Jan 2024 – Present
Vice-Chair of Research, Department of Pharmacotherapy	November 2022 – Present
Associate Professor	November 2022 – Present

Centers for Medicare and Medicaid Services

Special Advisor related to the Inflation Reduction Act	December 2022 – April 2023
--	----------------------------

Johns Hopkins University Carey Business School

Affiliate Scholar, Hopkins Business of Health Initiative	July 2021 – Present
--	---------------------

University of Maryland School of Pharmacy

Vice-Chair of Academic Affairs, Pharmaceutical Health Services	Dec 2019 – Jan 2023
Associate Professor	July 2019 – Jan 2023
Director of Operations, The PATIENTS Program	Sep 2016 – Jan 2023
Assistant Professor, Department of Pharmacy Practice and Science	April 2014 – July 2019

Omnicare, Inc.

Consultant Pharmacist	Feb 2014 – April 2014
-----------------------	-----------------------

AlixRx

Pharmacy Director / General Manager	July 2012 – Sep 2013
-------------------------------------	----------------------

The Kroger Company

Pharmacy District Manager (District 6 – Mid South)	Jan 2012 – July 2012
Pharmacy Manager (Stores L389, L366, L780, L191)	Feb 2010 – Jan 2012
Pharmacist and EPRN Super Trainer (Mid South)	March 2009 – Feb 2010
Pharmacy Technician / Intern	Jan 2004 – March 2009

AWARDS

Albert B. Prescott Pharmacy Leadership Award. National award presented by the Pharmacy Leadership and Education Institute (PLEI) and Phi Lambda Sigma	2019
Harris-Zuckerman Award. University of Maryland School of Pharmacy Department of Pharmaceutical Health Services Research	2017
Volunteer of the Year. Professional Fraternity Association	2017
Teacher of the Year. University of Maryland School of Pharmacy	2016, 2022
Honorary Advisor. University of Maryland School of Pharmacy Chapter, American Pharmacists Association Academy of Student Pharmacists	2016
Spirit Award. University of Maryland School of Pharmacy	2015
Distinguished Alumni Award. Phi Lambda Sigma, Beta Lambda Chapter	2015
Honorary Member. Rho Chi	2015
Kaplin Passmanek Award. University of Kentucky College of Pharmacy	2009
Ryan Travel Award. University of Kentucky College of Pharmacy	2008
J.C. and Rheba Cobb Scholarship. National Community Pharmacists Association	2008

GRANTS (Active)

“Behavioral symptoms of dementia/psychotropics use during COVID-19” Source: Alzheimer’s Association Role: PI; Amount: \$148,993	9/01/2023 – 08/31/25
“PRedicting Operational Sustainability and Patient- and pharmacist-level Effects for Retail pharmacies (PROSPER)” Source: ALSAM Foundation Role: Subcontract PI (PI: Anderson); Amount: \$150,000	7/01/2023 – 06/30/25
“Medical and Pharmacy Student Perceptions of a “First-Year-Free” Tuition Model.” Source: 1U4U (Internal Award) Role: PI; Amount: \$30,000	7/01/2023 – 06/30/24

GRANTS (Recently Submitted/Under Review)

“Evaluating Pharmacy and Medication Access for Medicare Enrollees.” Source: AHRQ (R01XX000000-01); <i>Review Date 10/01/2024</i> Role: Co-Investigator (PI: K. Anderson); Amount: \$1,200,000	7/01/2025 – 6/30/2028
“Improved Medication Cost Estimation to Narrow Unequal Adherence (MENU) Trial.” Source: NIMHD (R01XX000000-01); <i>Review Date 10/01/2024</i> Role: Co-Investigator (PI: K. Kawamoto); Amount: \$1,200,000	7/01/2025 – 6/30/2030
“Oral cephalosporins for Pyelonephritis IN the Emergency Department – OPINED Trial.” Source: PCORI (Broad PFA); <i>Review Date 10/01/2024</i> Role: Co-Investigator (PI: B. Faine); Amount: \$5,000,000	7/01/2025 – 6/30/2030

GRANTS (Not Funded / Planning to Resubmit)

“Center for Aging in Rural Environments (CARxE)” Source: NIA (R24AG089045-01); <i>Review Date 3/01/2024</i> Role: PI; Amount: \$1,932,023 Impact Score: 22 Plan: Revising for 2024 Cycle 3 submission	7/01/2024 – 6/30/2029
--	-----------------------

“Mountain West Medication Outcomes in Dementia Care Research Center” 7/01/2024 – 6/30/2029
 Source: NIA (U54AG089299-01); *Review Date 3/25/2024*
 Role: PI; Amount: \$18,918,786
Impact Score: Not Discussed
Plan: Revising U54 center components to fit separate, smaller grant RFAs.

GRANTS (Completed)

“COMMunity Mistrust & Institutional Trustworthiness to advance health EQUity research (COMMIT-EQ)” 4/01/2022 – 09/30/2023
 Source: FDA (U01FD007563)
 Role: Administrative PI (MPI: Baquet); Amount: \$1,000,000

“COMMunity Mistrust & Measures of Institutional Trustworthiness (COMMIT)” 1/01/2022 – 12/31/2023
 Source: NIMHD (U01MD017437)
 Role: MPI (Administrative PI: Mullins); Amount: \$1,196,222

“Understanding and Enhancing Diversity in Patient Engagement Activities for FDA CBER-Regulated Therapeutics” 1/01/2021 – 06/30/2022
 Source: Food and Drug Administration (U01FD005946-05S2)
 Role: Sub-Award PI (Parent PI: Polli); Amount: \$225,000 (21%)

“Resolve to Save Lives: Pharmacy Workforce Impact in India.” 10/01/2020 – 06/30/2022
 Source: Vital Strategies Foundation
 Role: Subcontract PI (Parent PI: Appel); Amount: \$34,567 (15% effort)

“Community Engagement Research Alliance (CEAL) Against COVID-19 Disparities” 5/15/2021 – 3/15/2022
 Source: NHLBI (P30AG028747-15)
 Role: Co-investigator (Parent PI: Himmelfarb)

“Is there a relationship between health literacy and patient preferences? A pilot study among breast cancer patients.” 07/02/2020 – 01/01/2022
 Source: Merck Investigator Initiated Study
 Role: Co-investigator (PI: Perfetto); Amount: \$157,382 (3% effort)

“Patient-Driven Priorities for the Management of Treatment-Resistant Depression.” 07/01/2020 – 12/31/2021
 Source: Innovation Value Institute
 Role: Co-investigator (PI: dosReis); Amount: \$87,580 (10% effort)

“Evidence Quality in Economic Evaluations.” 07/01/2020 – 06/30/2021
 Source: PhRMA
 Role: Co-investigator (PI: dosReis); Amount: \$43,143 (3% effort)

“#IDatHome: A Virtual Conference for Infectious Diseases-Focused Patient-Centered Outcomes Research” 12/1/2020 – 11/30/2021
 Source: PCORI Eugene Washington Engagement Award
 Role: PI, Amount: \$99,244 (8% effort)

<p>“Epicenters for the Prevention of Healthcare-Associated Infections” Supplement focus: “Nursing homes and COVID-19 Spread” Source: CDC National Center for Emerging and Zoonotic Infectious Diseases (5U01CK000556-02) Role: Section lead (Parent PI: A Harris); Amount: \$899,756 (20% effort)</p>	06/01/2020 – 05/31/2021
<p>“Engaging Caregivers to Understand Different Factors Related to Supporting a Child Treated for a Diaphyseal Femur Fracture.” Source: Subcontract award from Children’s National Role: PI; Amount: \$27,223 (0% effort due to grant restrictions)</p>	07/01/2020 – 12/31/2020
<p>“Delphi Panel to Engage Patients on the Value of Treatment for Food Allergy.” Source: PhRMA Role: PI, Amount: \$102,010 (20% effort)</p>	08/31/2019 – 06/27/2020
<p>“Resolve to Save Lives: Cardiovascular Health Online Course.” Source: Vital Strategies Foundation Role: Subcontract PI (Parent PI: Appel); Amount: \$25,000 (15% effort)</p>	03/31/2019 – 06/30/2020
<p>“Center for Patient-Driven Value Assessment.” Source: PhRMA Foundation Role: Co-investigator (PI: dosReis); Amount \$500,000 (3-7% effort)</p>	01/01/2018 – 12/31/2020
<p>“Use of Real-World Evidence in Value & Health Technology Assessment.” Source: Pfizer Role: Co-PI, methods lead (with E Perfetto); Amount \$91,998 (5% effort)</p>	09/01/2019 – 08/31/2019
<p>“Transparency in Selection of Sources of Published Input for Value and Health Technology Assessment.” Source: Excerpta Medica Role: Co-PI, methods lead (with E Perfetto); Amount \$38,991 (5% effort)</p>	09/01/2019 – 05/30/2019
<p>“Pharmapreneur: Role of Entrepreneurialism in Schools of Pharmacy.” Source: AACP New Investigator Award Role: PI, Amount: \$10,000</p>	02/01/2018 – 01/31/2019
<p>“PATIENTS: PATient-centered Involvement in Evaluating effectiveNess of TreatmentS.” Source: AHRQ (R24HS022135) Role: Co-investigator (PI: Mullins); Amount \$4,940,615 (20% effort)</p>	09/01/2016 – 08/31/2018
<p>“Engaging an Underserved Patient Community to Inform & Improve Comparative Effectiveness Research for Hepatitis C Treatments.” Source: PCORI Role: PI, Amount: \$50,000</p>	10/01/2017 – 09/30/2018
<p>“Development of a viral hepatitis cohort in a large commercially insured population to investigate co-infection with human immunodeficiency virus.” Source: Pharmaceutical Research Computing Role: PI, Amount \$15,000</p>	09/01/2017 – 05/30/2018
<p>“A single-center pilot to measure self-reported health confidence</p>	09/01/2017 – 06/30/2018

from a pharmacy discharge service & 30-day readmission rates.”

Source: Bristol Myers Squibb

Role: PI; Amount: \$74,500.

“Improving Clinical Outcomes in Gram-Negative Bacteremia through a 24-Hour Multidisciplinary Verigene® Gram-Negative Blood Culture Treatment Pathway” 07/01/2017 – 07-01-2018

Source: Making a Difference in Infectious Diseases (MAD-ID)

Role: Co-investigator (PI K Claeys); Amount \$27,222

“Cost-effectiveness of confirmatory penicillin skin testing in acute care settings.” 03/10/2017 – 03/09/2018

Source: Industry Sponsored Unrestricted Grant, ALK PRE-PEN®

Role: Co-PI (with E Heil); Amount: \$60,000

“Increasing Patient-Community Capacity to Engage on Quality of Health Care and Research and Programs.” 07/01/2016 – 06/30/2018

Source: PCORI

Role: Subcontract PI (Parent PI: E Perfetto); Subcontract Amount: \$25,000

Strategic Consultant 07/01/2017 – 06/30/2019

Source: University of Maryland Medical Center

Amount: 20% salary provided

PUBLICATION (Refereed/Peer Reviewed Journals)

The corresponding author is underlined; students and residents under my supervision are indicated with an asterisk. * ([Link to NCBI Bibliography](#))

1. Mattingly II TJ, Esterly AA, Kaltenboeck, A. Implementing Maximum Fair Price Without Hurting Pharmacies. *JAMA Health Forum*. 2024;5(5):e240921.
2. Slejko JF, Mattingly II TJ, Wilson A, Xie R, Chapman RH, Amill-Rosario A, dosReis S. Patient-Informed Value Elements for Economic Evaluation of Treatment for Major Depressive Disorder: A Literature Review and Synthesis. *Value in Health*. Online ahead of print, May 20, 2024. DOI: 10.1016/j.jval.2024.05.017.
3. Mattingly II TJ, Baquet CR, Lance F, Medeiros M, Mullins CD. Community-Academic Partnerships for Research: A transparent process of engagement before the research begins. *Ethnicity & Disease*. Accepted, in print March 2024.
4. Mattingly II TJ. A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments. *PharmacoEconomics*. 2024;42:253-259.
5. Mattingly II TJ, LaFleur G, Ruble JH. Comments on “GLP-1 agonists: A review for emergency clinicians. *Am J Emerg Med*. 2024;Apr 2:S0735-6757(24)00146-3. DOI: 10.1016/j.ajem.2024.03.034
6. Mattingly II TJ. Interpreting 340B contract pharmacy growth: who really benefits? *Health Affairs Scholar*. 2023;2(1): 1-2. DOI: 0.1093/haschl/qxad076.
7. Mattingly II TJ, Ben-Umeh KC, Bai G, Anderson GF. Pharmacy Benefit Manager Pricing and Spread Pricing for High-Utilization Generic Drugs. *JAMA Health Forum*. 2023;4(10):e233660.
8. Mattingly II TJ, Hyman DA, Bai G. Pharmacy Benefit Managers: History, Business Practices, Economics and Policy. *JAMA Health Forum*. 2023;4(11):e233804.
9. Mattingly II TJ, Anderson GF, Levy JF. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications. *JAMA Health Forum*. 2023;4(6):e231317.
10. Mattingly II TJ, Everson J, Besaw RJ, Whitmore CC, Henderson SC, Dusetzina SB. ‘Worth It If You Could Afford It’: Patient Perspectives on Integrating Real-Time Benefit Tools into Drug Cost Conversations. *J Am Geriatr Soc*. 2023;71(5):1627-1637. doi: 10.1111/jgs.18226.
11. Mattingly II TJ. Who Owns This Nursing Home? The Role of Private Equity in Long-Term Care. *Public Policy & Aging Report*. Epub 2023 Apr 27. DOI: 10.1093/ppar/prad007

12. Dusetzina SB, Besaw RJ, Whitmore CC, **Mattingly II TJ**, Sinaiko AD, Keating NL, Everson J. Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 and Older in the United States in 2022. *JAMA Network Open*. 2023;6(5):14211. DOI: 10.1001/jamanetworkopen.2023.14211
13. Anderson K, DiStefano M, Liu A, **Mattingly II TJ**, Socal M, Anderson G. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing into Medicare Payment for Expensive Part B Drugs. *Value in Health*. 2023;26(9):1381-1388. DOI: 10.1016/j.jval.2023.05.018
14. Huffman MK*, McGirt D*, Patil D*, **Mattingly II TJ**. Exploring pharmacy student experiences with student debt, burnout, and loan relief. *Am J Pharm Educ*. 2023;87(11):100134.
15. Blakely ML, Chahine E, Emmons R, Gorman E, Astle K, Martello JL, **Mattingly II TJ**, Nogid A, Pick A, Law Anandi V. Report of the 2020-2021 AACP Faculty Affairs Standing Committee: Best Practices for Faculty Self-Advocacy. *Am J Pharm Educ*. 2023;87(8):100045.
16. Holtorf AP, Danyliv A, Krause A, Hanna A, Venable Y, **Mattingly II TJ**, Huang LY, Pierre M, Silveira Silva A, Walsh D. Ethical and legal considerations in social media research for health technology assessment: conclusions from a scoping review. *Int J Technol Assess Health Care*. 2023 Oct 16;39(1):e62. doi: 10.1017/S0266462323000399
17. Holtorf AP, Danyliv A, Huang LY, Venable Y, Hanna A, Krause A, Pierre M, Walsh D, Silveira Silva A, Lee SH, **Mattingly II TJ**. Using social media research in health technology assessment: stakeholder perspectives and scoping review. *Int J Technol Assess Health Care*. 2023 Sep 21;39(1):e63. doi: 10.1017/S0266462323002593
18. Xue P, Zisman E, Patel P, Jakhete N, Sakiani S, **Mattingly II TJ**, Shetty K. A Description of Resource Utilization and Costs in Acute on Chronic Liver Failure. *Progress in Transplantation*. 2023. DOI: 10.1177/15269248231189876.
19. Owens JA, **Mattingly II TJ**, Foote JD, Okoye GE, Nguyen VAT, Pribil SL, Lilly FRW. Donations wanted: Assessing online medical crowdfunding campaigns created for dementia care. *J Am Geriatr Soc*. 2023;71(9):2979-2983. doi: 10.1111/jgs.18391.
20. **Mattingly II TJ**. Death, Taxes, and Tuition Increases. *Am J Pharm Educ*. 2023 Mar;87(2):ajpe9068. doi: 10.5688/ajpe9068. 2023;87(2):Article 9068. PubMed PMID: 35418447.
21. Oehrlein EM, Schoch S, Burcu M, McBeth J, Bright J, Pashos CL, Willke R, Love TR, **Mattingly II TJ**, Perfetto EM. Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process. *Value in Health*. 2023;26(1):28-38. DOI: 10.1016/j.jval.2022.04.1738
22. **Mattingly II TJ**, Shetty K. The economics of advanced and unresectable hepatocellular carcinoma. *Cancer*. 2022;128(22):3907-09. DOI: 10.1002/cncr.34456
23. **Mattingly II TJ**, Fernandez VD, Seo D, Melgar Castillo AI. A review of caregiver costs included in cost-of-illness studies. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2022;22(7):1051-60. DOI: 10.1080/14737167.2022.2080056
24. Everson J, Whitmore C, **Mattingly II TJ**, Sinaiko A, Dusetzina S. Physician Perspectives on Implementation of Real-Time Benefit Tools: A Qualitative Study. *Appl Clin Inform*. 2022 Sep 19. doi: 10.1055/a-1947-2674.
25. **Mattingly II TJ**, Lewis M, Socal MP, Bai G. State-level policy efforts to regulate pharmacy benefit managers (PBMs). *Res Social Adm Pharm*. 2022 Nov;18(11):3995-4002. doi: 10.1016/j.sapharm.2022.07.045.
26. **Mattingly II TJ**, Weathers S. Drug Costs in Context: Assessing drug costs in cost-of-illness analyses. *Drugs in Context*. 2022;11:2022-5-4. DOI: 10.7573/dic.2022-5-4
27. **Mattingly AN**, **Mattingly II TJ**, Phan AL, Negash K,. Categorization and comparisons of drug recalls for manufacturers and compounders. *J Am Pharm Assco*. 2022;62:1344-1350. DOI:10.1016/j.japh.2022.03.010
28. Khokhar B, Weathers S, **Mattingly II TJ**. Direct-to-consumer advertising and the advancement of the quadruple aim: A narrative review. *JACCP: J Am College of Clin Pharm*. 2022;5:459-466. DOI: 10.1002/jac5.1599
29. **Mattingly II TJ**, Conti RM. American must consider paying more for essential drugs to ensure their high quality and resilient supply. *J Manag Care Spec Pharm*. 2022;28(5):573-6. DOI: 10.18553/jmcp.2022.28.5.573
30. **Mattingly II TJ**, Wolff JL. Caregiver Economics: A framework for estimating the value of the American Jobs Plan for a caring infrastructure. *J Am Geriatr Soc*. 2021;69(8):2370-3. DOI: 10.1111/jgs.17269.

31. **Mattingly II TJ**, Trinkoff A, Lydecker A, Kim J, Yoon, Roghamann MC. Short-stay admissions associated with larger COVID-19 outbreaks in Maryland nursing homes. *Gerontology & Geriatric Medicine*. 2021;7. DOI: 10.1177/233372142111063103.
32. **Mattingly II TJ**, McQueen RB, Lin PJ. Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies. *PharmacoEconomics*. 2021;39(10):1101-7. DOI: 10.1007/s40273-021-01079-6.
33. Yuen S*, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, **Mattingly II TJ**. A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. Submitted to *PharmacoEconomics – Open*. 2022;6:9-19. DOI: 10.1007/s41669-021-00298-z
34. Bissell BD, Johnston JP, Smith RR, Newsom AS, Bastin MLT, Abdul-Mutakabbir J, Barlow A, Barlow B, Berger K, Crow JR, Dixit D, Jacobi J, Karaoui LR, Kiser TH, Kolesar J, Koontz SE, **Mattingly II TJ**, Mitchell C, Nilges A, Rech MA, Heavner M. Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. *AJHP*. 2021;78(22):2059-2076. DOI: 10.1093/ajhp/zxab275.
35. **Mattingly II TJ**, Weathers S. Direct and Indirect Effects of Restrictive Immigration Policies on Pharmacy Education. *American Journal of Pharmaceutical Education*. 2021;85(5). DOI: 10.5688/ajpe8534
36. **Mattingly II TJ**. PCORI's Expanded Mandate Creates New Opportunities for Value Assessment Research. *Am J Accountable Care*. 2021;9(3):19-21. DOI: 10.37765/ajac.2021.88720
37. Abdelwadoud M, Eftekhari S, Jaffee H, Carver M, **Mattingly II TJ**. Food Allergy Treatment Value: Caregiver and Patient Perspectives. Online ahead of print February 5, 2021. DOI: 10.1111/pai.13464.
38. Alderfer J, Hansen RA, **Mattingly II TJ**. Understanding Authorized Generics – A review of the Published Clinical Data. *Journal of Clinical Pharmacy and Therapeutics*. Online ahead of print April 8, 2021. DOI: 10.1111/jcpt.13426.
39. Shafirin J, Graf M, Tuly R, Glaetzer C, Hickson S, **Mattingly II TJ**. We have a vaccine, now what? How to ensure continued COVID-19 vaccine discovery and expedite access. *Journal of Clinical Pathways*. 2021;7(1):46-48. DOI: 10.25270/jcp.2021.02.00002.
40. Abdelwadoud M*, **Mattingly II TJ**, Segui HA, Gorman EF, Perfetto EM. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. *The Patient*. 2020;14:471-484. DOI: 10.1007/s40271-020-00489-6.
41. **Mattingly II TJ**, Seo D, Ostrovsky AM, Vanness DJ, Conti RM. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad. *Research in Social and Administrative Pharmacy*. 2021;17(8):1489-95. DOI: 10.1016/j.sapharm.2020.11.007
42. **Mattingly II TJ**, Kiser L, Hill S, Briggs EC, Trunzo CP, Zafari Z, Betancourt TS. Unseen Costs: Estimated Direct and Indirect Impact of US Immigration Policies on Child Health and Well-Being. *Journal of Traumatic Stress*. 2020;33(6):873-881. DOI: 10.1002/jts.22576.
43. **Mattingly II TJ**, Li K, Ng A, Ton-Nu T, Owens J. Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe. *PharmacoEconomics Open*. 2021;5:245-250. DOI: 10.1007/s41669-020-00232-9.
44. Linthicum M, dosReis S, Slejko JF, **Mattingly II TJ**, Bright J. The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment. *The Patient*. 2021;14(4):381-384 DOI: 10.1007/s40271-020-00446-3
45. Livingston AN*, **Mattingly II TJ**. Drug and medical device product failures and the stability of the pharmaceutical supply chain. *J Am Pharm Assoc*. 2021;61(1):e119-e122. DOI: 10.1016/j.japh.2020.07.005.
46. **Mattingly II TJ**, Love BL, Khokhar B. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. *PharmacoEconomics*. 2020;38:927-939. DOI: 10.1007/s40273-020-00933-3. Available at: <https://rdcu.be/b4S7m>
47. **Mattingly II TJ**, Shere-Wolfe K. Clinical and economic outcomes evaluated in Lyme Disease: a systematic review. *Parasites & Vectors*. 2020;13:34. DOI: 10.1186/s13071-020-04214-y. Available: <https://rdcu.be/b5xIK>
48. **Mattingly II TJ**. The economics of drug allergy. *Current Opinion in Allergy & Clinical Immunology*. 2020;20(4):395-400. DOI: 10.1097/ACI.0000000000000651.
49. **Mattingly II TJ**. Elimination of hepatitis C virus infection in Canada is achievable, but is the rest of the world ready to join in this effort? *JAMA Network Open*. 2020;3(5):e204355.
50. **Mattingly II TJ**, Heil EL. The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface. *Clinical Infectious Diseases*. 2021;72(6):939-941.

51. **Mattingly II TJ**, Hogue MD. Pharmacy's Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging. *J Manag Care Spec Pharm*. 2020;April 24:1-4. DOI: 10.18553/jmcp.2020.20166.
52. **Mattingly II TJ**, Love BL. Changes in cost-effectiveness for chronic hepatitis C virus pharmacotherapy: The case for continuous cost-effectiveness analyses. *J Manag Care Spec Pharm*. 2020;26(7):879-886. DOI: 10.18553/jmcp.2020.26.7.879.
53. **Desai B**, **Mattingly II TJ**, van den Broek R, Pham N, Frailer M, Yang J, Perfetto EM. Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment. *Value in Health*. 2020;23(6):689-696. Available at: <https://doi.org/10.1016/j.jval.2020.01.014>
54. **Tran D**, **Mattingly II TJ**, Sera L. Building confidence: Three-year evaluation of systematic progression of prescription verification on students' confidence during IPPE. *Currents in Pharmacy Teaching and Learning*. 2020;12(4):388-394. DOI: 10.1016/j.cptl.2019.12.036.
55. **Mattingly II TJ**, Slejko JF, Onukwugha E, Perfetto EM, Kottlil S, Mullins CD. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. *Pharmacoeconomics*. 2020;38:233-242. DOI: 10.1007/s40273-019-00864-8. Available: <https://rdcu.be/bYbA7>
56. **Slejko JF**, **Mattingly II TJ**, dosReis S. The Future of Patient-Driven Healthcare Evaluation: The Patient-informed Reference Case. *Value in Health*. 2019;22(5):545-8. DOI: 10.1016/j.jval.2019.02.003.
57. **Mattingly II TJ**. Before we talk about student debt cancelation, can we talk about the interest rates? *Am J Pharm Educ*. 2019;83(9):Article 7761. Available: <https://www.ajpe.org/content/83/9/7761>
58. **Mattingly II TJ**, Slejko JF, Perfetto EM, Kottlil S, Mullins CD. What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism. *The Patient*. 2019;12:631-638. DOI: 10.1007/s40271-019-00378-7.
59. Dahmane E, Tang K, Gobburu J, **Mattingly II TJ**, Reed BN, See VY, Ayres J, **Ivaturi V**. Clinical Pharmacology Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy. *Clin Transl Sci*. 2019. Online ahead of print, July 22, 2019. DOI: 10.1111/cts.12670.
60. **Kennedy D**, Harrell K, Lodise N, **Mattingly II TJ**, Norenberg J, Ragucci K, Ranelli P, Stewart A. Current Status and Best Practices of Shared Governance within US Pharmacy Programs. *Am J Pharm Educ*. 2020;84(7):ajpe7281. DOI: 10.5688/ajpe7281
61. **Smith T**, **Mattingly TJ**, Slabaugh L. Improving health determinants outside of the clinic does not mean outside of clinical science. *Healthcare*. 2019;7(4). DOI: 10.1016/j.hjdsi.2019.06.001.
62. **Mattingly II TJ**, Abdelwadoud M, Mullins CD, Eddington ND. Pharmapreneur – Defining a Framework for Entrepreneurship in Pharmacy Education. *Am J Pharm Educ*. 2019;83(10):Article 7548.
63. **Mattingly II TJ**. 2019 Prescott Lecture: The Case for Authentic Leadership. *J Am Pharm Assoc*. 2019;59:e12-e15. DOI: 10.1016/j.japh.2019.05.018.
64. **Urlick BY**, **Mattingly II TJ**, Mattingly AN. Relationship between Regulatory Barriers to Entry and Pharmacy Technician Wages. *Research in Social and Administrative Pharmacy*. 2019. Online ahead of print May 17, 2019. DOI: 10.1016/j.sapharm.2019.05.003.
65. **Reed BN**, Klutts A, **Mattingly II TJ**. Leadership in Pharmacy: A Systematic Review of Definitions, Competencies, and Assessment Methods. *Am J Pharm Educ*. 2019;83(9): Article 7520. DOI: 10.5688/ajpe7520. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920635/>
66. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, **Mattingly TJ**, Campbell JD, Allen J, Ferris AE, Schilsky R, Danielson D, Lichtenfeld JL, House L, Selig W. The Promise of Immuno-Oncology: Implications for Defining the Value of Cancer Treatment. *J Immunother Cancer*. 2019;7(1):129. DOI: 10.1186/s40425-019-0594-0.
67. **Mattingly II TJ**, Pandit NS, Onukwugha E. Burden of Co-Infection: A cost analysis of human immunodeficiency virus in a commercially insured hepatitis C virus population. *Infect Dis Ther*. 2019;8(2):219-228. doi: 10.1007/s40121-019-0240-7.
68. **Mattingly II TJ**, Meninger S, Heil EL. Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis. *PLoS ONE*. 2019;14(1): e0210271. DOI: <https://doi.org/10.1371/journal.pone.0210271>.
69. **Mattingly II TJ**, Nong K. Implementing a health confidence tool at time of discharge. *Patient*. 2019;12(1):163-165. DOI: 10.1007/s40271-018-0343-3.
70. **Mattingly II TJ**, Mullins CD, Melendez DR, Boyden K, Eddington ND. Entrepreneurship in Pharmacy Practice and Education: A Systematic Review. *Am J Pharm Educ*. 2019;83(3): Article 7233. DOI: 10.5688/ajpe7233. Available: <https://www.ajpe.org/content/83/3/7233>

71. **Mattingly II TJ**, Levy JF, Slejko JF, Onwudiwe NC, Perfetto EM. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References? *PharmacoEconomics*. 2018;36(9):1093-1099. DOI: 10.1007/s40273-018-0667-9.
72. **Mattingly II TJ**, Perfetto EM, Johnson S. Engaging hepatitis C infected patients in cost-effectiveness analyses: a literature review. *Hepatology*. 2018;67(2):774-81. DOI: 10.1002/hep.29482.
73. **Mattingly II TJ**. Is there room for efficiency in pharmacy education? *Am J Pharm Educ*. 2018;82(9): Article 7271. DOI: 10.5688/ajpe7271
74. **Mattingly II TJ**. APhA adopts actionable policy once again. *J Am Pharm Assoc*. 2018;58(4):334-5. DOI: 10.1016/j.japh.2018.06.007
75. Mattingly AN, **Mattingly II TJ**. Regulatory burden and salary for pharmacy technicians in the United States. *Research in Social and Administrative Pharmacy*. Online ahead of print July 11, 2018. DOI: 10.1016/j.sapharm.2018.07.009
76. **Mattingly II TJ**, Fulton A, Lumish R, Williams A, Yoon S, Yuen M, Heil EM. The cost of self-reported penicillin allergy: a systematic review. *JACI: In Practice*. 2018;6(5): 1649-1654.e4. DOI: 10.1016/j.jaip.2017.12.033
77. Wu T, Williams C, Vranek K, **Mattingly II TJ**. Using 340B Drug Discounts to Provide a Financially Sustainable Medication Discharge Service. *Research in Social and Administrative Pharmacy*. Online March 27, 2018. DOI: 10.1016/j.sapharm.2018.03.065
78. **Mattingly II TJ**. Measuring pharmacy technician impact on desired outcomes. *J Am Pharm Assoc*. 2018;58(1):8-9. DOI: 10.1016/j.japh.2017.12.002.
79. Mattingly AN, **Mattingly II TJ**. Advancing the role of the pharmacy technician: A systematic review. *J Am Pharm Assoc*. 2018;58(1):94-108. DOI: 10.1016/j.japh.2017.10.015.
80. **Mattingly II TJ**, Simoni-Wastila L. Patient-Centered Drug Approval: The role of patient advocacy in the drug approval process. *Journal of Managed Care & Specialty Pharmacy*. 2017;23(10):1078-82. DOI: 10.18553/jmcp.2017.23.10.1078
81. **Mattingly II TJ**, Slejko JF, Mullins CD. Hepatitis C treatments are cost-effective – but compared to what? *Annals of Pharmacotherapy*. 2017;51(11):961-9. DOI: 10.1177/1060028017722007
82. Yu J, Pincus KJ, **Mattingly II TJ**. Service description and descriptive analysis for an interprofessional discharge clinic (IDC) with a primary care practice. *Journal of Interprofessional Care*. 2017;31(6):771-3. DOI: 10.1080/13561820.2017.1347611
83. Dunn EE*, Vranek K, Hynicka L, Gripshover J, Potosky D, **Mattingly II TJ**. Improving prior authorization efficiency in the treatment of hepatitis C virus (HCV) in an academic medical center. *Quality Management in Health Care*. 2017;26(3):136-9. DOI: 10.1097/QMH.0000000000000137
84. **Mattingly II TJ**, Ulbrich TR. Evaluating the Changing Financial Burden for Graduating Pharmacists. *Am J Pharm Educ*. 2017;81(7): Article 5990. DOI: 10.5688/ajpe5990
85. **Mattingly II TJ**, Romanelli F, Cain J, Schlesselman LS. Measuring Up: Defining the Quality of PharmD Programs. *Am J Pharm Educ*. 2017;81(9):Article 6071. DOI: 10.5688/ajpe6071
86. Hindman FM*, Bukowitz A*, Reed BN, **Mattingly II TJ**. No Filter: A characterization of #pharmacists posts on Instagram. *J Am Pharm Assoc*. 2017;57(3):318-325. DOI: 10.1016/j.japh.2017.01.009.
87. **Mattingly II TJ**, Heil EL, Hoke KS. Exploring the case for eminent domain of hepatitis C virus treatment patents. *Journal of Health Care for the Poor and Underserved*. 2017;28(2):621-625. DOI: 10.1353/hpu.2017.0062
88. **Mattingly II TJ**, Mullins CD, Onukwugha E. Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter? *Pharmacoeconomics*. 2016;34(10):1067-70. DOI: 10.1007/s40273-016-0438-4.
89. Feemster AA, **Mattingly II TJ**. Multiple Bosses: Challenges and suggestions to improve organizational environments in academic settings. *INNOVATIONS in pharmacy*. 2016; 7(2):7.
90. **Mattingly II TJ**, Tom SE, Stuart B, Onukwugha E. Examining patient-provider relationship (PPR) quality and patient activation. *Aging Clinical and Experimental Research*. 2016;29(3):543-548. DOI: 10.1007/s40520-016-0600-z
91. Miklich MA, Reed BN, **Mattingly II TJ**, Haines ST. Beliefs and behaviors of professionally engaged pharmacists. *Journal of the American Pharmacists Association*. 2016; 56(4):405-11. DOI: 10.1016/j.japh.2016.03.011.
92. **Mattingly II TJ**. A review exploring the relationship between nursing home staffing and antipsychotic medication use. *Neurol Ther*. 2015;1-7. DOI: 10.1007/s40120-015-0032-2.

93. **Mattingly II TJ**. Innovative patient care practices using social media. *J Am Pharm Assoc.* 2015; 10:e295-300. DOI: 10.1331/JAPhA.2015.14171.
94. **Mattingly II TJ**. Rescheduling of Combination Hydrocodone Products: Problems for Long-Term Care Practitioners. *The Consultant Pharmacist.* 2015; 30(1):13-7. DOI: 10.4140/TCP.n.2015.13.
95. **Mattingly II TJ**, Cain J, Fink JL. Pharmacists on Facebook: online social networking and the profession. *J Am Pharm Assoc.* 2010;50(3):424-427. DOI: 10.1331/JAPhA.2010.08174.
96. **Weitzel KW**, Tisdale JE, **Mattingly J**. APhA2009 House of Delegates: Serving the Association and the profession. *J Am Pharm Assoc.* 2009;49(4):474-80. DOI:10.1331/JAPhA.2009.09520.
97. **Lutz EM**, Rovers J, **Mattingly J**, Reed BN. Pharmacy practice around the world. *J Am Pharm Assoc.* 2009;49(1):4-11. DOI:10.1331/JAPhA.2009.09500.

MANUSCRIPTS IN PROCESS

1. Seo D*, Patil D, Choi J, Gorman EF, Senghor A, Baquet CR, **Mattingly II TJ**. Identification of barriers to and practical strategies for increasing clinical trial diversity: A scoping review. *Clinical Trials*. Submitted March 2024.
2. **Seo D***, Rizk JG, **Mattingly II TJ**, Onukwugha E. Impact of Manufacturer-Initiated List Price Reduction on Patient Out of Pocket Costs for PCSK9 Inhibitors. *J Manag Care Pharm*. Submitted April 2024.
3. Duru EE*, Ben-Umeh, KC, **Mattingly II TJ**. Cost of Long-term Care and Balancing Caregiver Wellbeing: A Review. *Expert Review of Pharmacoeconomics and Outcomes Research*. Submitted April 2024, revisions due June 2024.
4. **Forrester P***, Senghor AS*, Mullins CD, Medeiros M, Baquet CR, Wright DL, **Mattingly II TJ**. Best Practices for CEnR Partnerships for Health Equity. *Progress in Community Health Partnerships: Research, Education, and Action*. Submitted May 2024.
5. Seo D*, Patil D*, Vandigo J, **Mattingly II TJ**. Consideration for Health Disparities in Value Assessment Frameworks. *ClinicoEconomics and Outcomes Research*. Submitted April 2024.
6. **Babin JL**, Raber H, **Mattingly II TJ**. Prompt Pattern Engineering for Test Question Mapping using ChatGPT: A cross-sectional study. *Am J Pharm Educ*. Submitted May 2024.
7. **LaFleur G***, **Mattingly II TJ**. Pharmacy school affordability for pharmacy technicians from 2004 to 2022. *Am J Pharm Educ*. Submitted May 2024.
8. **Mattingly II TJ**, Towse A, Garrison LP. Recommendations for Robust Evidence Synthesis to Support a Transparent Medicare Drug Price Negotiation Process. *Health Affairs*. Submitted May 2024.
9. **Anderson KE***, DiStefano MJ, Sahu M, Asche CV, **Mattingly II TJ**. Effect of Pharmacy Closures on Anticonvulsant Medication Use. *J Am Med Assoc*. Submitted May 2024.

CREATIVE ENDEAVORS IN CLINICAL PRACTICE

Pharmacy Department Scheduling Satisfaction

January 2016 – July 2022

University of Maryland Medical Center

Description of Service: Developed structured interview survey for pharmacy department employees around satisfaction constructs for the employee schedule, centralized scheduling process, and manager participation in scheduling.

Bedside Delivery Program

July 2014 – June 2018

University of Maryland Medical Center

Weinberg Outpatient Pharmacy

Description of Service: Collaborated with Kathryn Vranek to create and implement a discharge medication delivery service from the Weinberg Outpatient Pharmacy, piloting with the 6th floor cardiac surgery units.

Hepatology Prior Authorization Process Improvement Program

October 2014 – June 2017

University of Maryland Medical Center

Redwood Outpatient Pharmacy & Division of Gastroenterology

Description of Service: Collaborated with Kathryn Vranek to create and implement a new pharmacy-led prior authorization and transition of care service to streamline patients treated on novel Hepatitis C treatment.

Emergency Department Remote Pharmacy

January 2015 – June 2016

University of Maryland Medical Center

Weinberg Outpatient Pharmacy

Description of Service: Collaborated with Bryan Hayes to build the business proposal to launch a discharge medication dispensing service from the Emergency Department within UMMC. Successful launch of service in December of 2015 and currently reviewing initial data.

Oncology Collaboration: Mail-Order Neulasta Implementation

January 2015 – June 2016

University of Maryland Medical Center

Lithicum Specialty Pharmacy & Stoler Outpatient Infusion Center

Description of Service: To reduce the use of Neulasta (pegfilgrastim) in the outpatient infusion center by providing home delivery of the medication from the UMMC Specialty Pharmacy at Lithicum.

PRESENTATIONS (Scientific/Professional Meetings)

1. **Mattingly J.** Invited speaker on “Improving Health Disparity Evidence Gaps in Economic Evaluation.” Colorado Pragmatic Research in Health (COPRH) Conference. Virtual. June 5, 2024.
2. **Mattingly J.** Panel Presenter on: “Global Harmonization for Patient Focused Drug Development (PFDD): What Are the Arguable Challenges for Pragmatic Guideline Uptake and Implementation and How Should We Negotiate and Navigate Alignment?” International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting, Atlanta, Georgia, May 6, 2024.
3. **Mattingly J.** Invited speaker on “Prescription Drug Pricing 101” for the Journal of Health Care Law and Policy Spring Symposium in Baltimore, Maryland on March 7, 2024.
4. **Mattingly J.** Invited speaker on Pharmacy Benefit Manager (PBM) policy reforms for the National Association of Insurance Commissioners (NAIC) Annual Insurance Summit. Kansas City, Missouri, September 14, 2023.
5. **Mattingly J.** Invited panelist to present drug price myths and Pharmacy Benefit Manager (PBM) policy proposal implications for the National Conference of Insurance Legislators (NCOIL). Minneapolis, Minnesota, July 20, 2023.
6. **Mattingly J.** Invited panelist for discussion on value assessment for the 2021 Arthritis Healthcare Forum in Washington, DC on Tuesday December 7, 2021.
7. Zelenkofske S, Kalteneboeck A, Ollendorf D, **Mattingly J.** *Navigating the Pricing and Reimbursement Environment with Memorial Sloan, CEVR, and PAVE.* 8th Annual Chief Medical Officer Summit, virtual panel, October 26, 2020.
8. **Mattingly J,** Emond S, Foxworth P, Lavelle T, Whittington M. *Including the perspectives of patients in value assessments.* Society for Medical Decision Making 42nd Annual Meeting. October 20, 2020.
9. Huang Y, Sadownik S, Nasuti LJ, **Mattingly II TJ,** Auerbach D, Seltz D. Utilization and Spending Impact of Prescription Drug Coupons in Massachusetts. AcademyHealth 2020 Annual Research Meeting, Boston, MA, June 13-16, 2020.
10. Gatwood J, Eckel S, Holdford D, **Mattingly J.** Changing the Profession through Entrepreneurship and Innovation Education. American Association of Colleges of Pharmacy Annual Meeting, Chicago, Illinois, July 17, 2019.
11. **Mattingly II TJ,** Abdelwadoud M, Mullins CD, Eddington ND. A Framework for Entrepreneurship in Pharmacy Education. American Association of Colleges of Pharmacy Annual Meeting, Chicago, Illinois, July 14, 2019.
12. **Mattingly II TJ,** Love BL. *Temporal changes in cost-effectiveness for chronic Hepatitis C virus pharmacotherapy.* Podium presentation at the International Society of Pharmacoeconomics and Outcomes Research 24th Annual International Meeting, New Orleans, Louisiana, May 21, 2019.

13. Meninger S*, **Mattingly II TJ**, Heil EL. *Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia*. Presented at the Infectious Disease Society of America Annual ID Week Meeting, San Francisco, CA, October 5, 2018
14. Mattingly AN, **Mattingly II TJ**. *The relationship between pharmacy technician qualifications and salary in the United States*. Presented at the International Pharmaceutical Federation Annual Meeting, Glasgow, Scotland, September 2-6, 2018.
15. Nong K*, **Mattingly II TJ**. *The impact of self-reported health confidence at discharge: a single-center pilot study*. Academy of Managed Care & Specialty Annual Meeting, Boston, Massachusetts, April 23-26, 2018.
16. Chirico J, Williams C, Watt I, **Mattingly II TJ**. *Analysis of cost savings associated with pharmacist interventions within the electronic medical record*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 5, 2017.
17. Fulton A*, **Mattingly II TJ**, Heil E. *Risk Factors for Invalid Immunoglobulin E Mediated Penicillin Skin Testing Results in an Inpatient Setting*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 5, 2017.
18. **Mattingly II TJ**, Rocafort PT, Mattingly AN. *Business Plan Competition: Train-the-Trainer Program*. Invited workshop National Community Pharmacists Association Annual Meeting, Orlando, Florida. October 15, 2017.
19. **Mattingly II TJ**. *Mapping the curriculum continuous quality improvement (CQI) process*. American Association of Colleges of Pharmacy Annual Meeting, Nashville, Tennessee, July 18, 2017
20. **Mattingly II TJ**, Romanelli F, Cain J, Schlesselman LS. *Defining and Measuring the Quality of PharmD Programs: A Delphi Process*. American Association of Colleges of Pharmacy Annual Meeting, Nashville, Tennessee, July 17, 2017.
21. Onwudiwe NC, Slejko J, **Mattingly J**, Levy J. *W14: Transferability Of Economic Evaluation Studies: Is There A Generally Accepted Alternative Price Benchmark To The WAC Price?* Invited Workshop at the International Society of Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting, Boston, Massachusetts, May 23, 2017.
22. **Mattingly II TJ**. *Pharmacists' Role in the Provision of HIV Care*. Invited presentation at the 13th Annual HIV in West Virginia Conference, Roanoke, West Virginia, April 27, 2017.
23. **Mattingly II TJ**. *Emotional Intelligence*. Invited presentation at the American Pharmacists Association Annual Meeting & Exposition, San Francisco, California, March 26, 2017.
24. Wu T*, Williams C, Vranek K, **Mattingly II TJ**. *Cost-benefit analysis of bedside delivery service from a health-system perspective*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 2016.
25. Yu J*, Pincus KJ, **Mattingly II TJ**. *Service description and descriptive analysis for an interprofessional discharge clinic (IDC) within a primary care practice*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 2016.
26. Joachim AC*, Kim J*, Vranek K, **Mattingly II TJ**. *Why are specialty pharmaceuticals so special?* American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 2016.
27. Park S*, **Mattingly II TJ**, Duffy A, Gilmore S. *Assessment of a multi-discipline implemented pegfilgrastim cost-minimization guideline: knowledge, adherence, safety, and patient-reported satisfaction*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 2016.
28. Tavakoli F*, **Mattingly II TJ**, Pandit NS. *Real life medication adherence with newer hepatitis C treatments and their effect on sustained virologic response (SVR)*. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 2016.
29. **Mattingly II TJ**, Slejko JF, Mullins CD. *Cost-Effectiveness of Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C Virus*. International Society for Pharmacoeconomics and Outcomes Research Annual European Congress, Vienna, Austria, November 1, 2016.
30. **Mattingly II TJ**, Krenning M, Clough B, Tuell K. *Real World Outcomes and Performance of Specialty Pharmacy*. National Association of Specialty Pharmacy Annual Meeting & Exposition, Washington, DC. September 27, 2016.
31. **Mattingly II TJ**, Mullins CD, Onukwugha E. *Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?* International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Washington, DC, May 25, 2016.

32. Okoro C*, Gripshover J, **Mattingly II TJ**. *The impact of direct acting antiviral (DAA) therapy on renal function in diabetic patients with hepatitis C virus (HCV)*. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, California. April 20, 2016.
33. Miklich M*, Pandit NS, Heil E, Hynicka L, Vranek K, **Mattingly II TJ**. *Hepatitis C Treatment Interruptions in Patients Treated with ledipasvir/sofosbuvir at Three Ambulatory Care Clinics*. American Pharmacists Association Annual Meeting, Baltimore, Maryland. March 7, 2016.
34. Moss M, Ravichandran B, **Mattingly II TJ**, Vranek K, Husson J, Haririan A. *Impact of Clinical Pharmacists in Hepatitis C Virus (HCV) Outpatient Clinic*. American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana. December 7-9, 2015.
35. Dunn EE*, **Mattingly II TJ**, Vranek K, Allen K, Hynicka L, Gripshover J, Potosky DR. *Evaluating a team-based approach to improve health-system navigation and efficiency in the treatment of hepatitis C virus (HCV)*. American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana. December 7-9, 2015.
36. Park HL*, Williams C, Grover B, Hayes B, **Mattingly II TJ**. *Capturing the Value of Clinical Pharmacy Services*. American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana. December 7-9, 2015.
37. Keung J*, Vranek K, **Mattingly TJ II**. *Impact of Medication Synchronization on Mail Order Pharmacies*. American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana. December 7-9, 2015.
38. **Mattingly II TJ**, Tom SE, Stuart B, Onukwugha E. *Examining the relationship between patient-doctor relationship (PDR) quality on patient activation in the Medicare population*. American Society of Consultant Pharmacists Annual Meeting. Las Vegas, Nevada. October 31, 2015.
39. Coop A, Dalby RN, Layson-Wolf C, Lebovitz L, Tucker SR, **Mattingly J**, Brandt NL. *Pharmacy Curriculum Outcomes Assessment (PCOA). Love it or Hate it, It's Required*. American Association of Colleges of Pharmacy Annual Meeting. National Harbor, Maryland. July 7, 2015.
40. Kowcz A*, Okoro C*, **Mattingly J**, Vranek K, Pincus KJ, Onukwugha E, Layson-Wolf C. *Evaluation of Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores with pharmacist-initiated bedside delivery program*. The American Pharmacists Association Annual Meeting. San Diego, California. March 2015.
41. **Mattingly TJ**, Brandt N, Warnock R. *Connecting the Dots: Process Improvement in Long Term Care*. American Society of Consultant Pharmacists Annual Meeting, Orlando, Florida. November 7, 2014.

PRESENTATIONS (Other Invited)

1. **Mattingly J**. Understanding the Nuances of Drug Pricing. 21st Annual Market Access Summit, October 6, 2021. Available at: <https://www.marketaccesscanada.ca/speakers/joey-mattingly/>
2. **Mattingly J**. Understanding the ABCs of Drug Pricing. International webinar sponsored by Wolters Kluwer and hosted by Xtelligent Healthcare on April 22, 2021.
3. **Mattingly J**. Alternative payment strategy. Indiana Pharmacists Association meeting on April 1, 2021.
4. **Mattingly J**. Invited lecturer on innovation and entrepreneurship for faculty of Touro College of Pharmacy, webinar format on April 15, 2021.
5. Stone P, Bright J, Emond S, **Mattingly J**, Westrich K. *Reflections from Stakeholders: What's Possible?* National Health Council and National Alliance of Healthcare Purchaser Coalitions Patient and Employer Roundtable on Value Assessment, November 13, 2020.
6. **Mattingly J**. *Understanding Drug Pricing Around the Globe*. International Society for Pharmacoeconomics and Outcomes Research Student Network Educational Webinar, April 8, 2020.
7. **Mattingly J**. *Rare Access Forum Panel* hosted by Haystack Project and Rare Cancer Policy Coalition. Washington, DC, February 25, 2020.
8. **Mattingly J**. *Incorporating the Patient Voice in Cost-Effectiveness Analysis Development*. Invited lecturer at Tufts University. Boston, Massachusetts, November 19, 2019.
9. **Mattingly J**. *Patient-Centered Cost-Effectiveness: Can Patient Engagement Improve Economic Evaluations?* Invited speaker at the Industry Partners Roundtable by the National Alopecia Areata Foundation. Washington, DC, September 11, 2019.
10. **Mattingly J**. *A Primer on Value Assessment and the Lingo*. Invited speaker at a day-long conference hosted by the National Health Council. Washington, DC, September 6, 2019.
11. **Mattingly J**. *Business Strategy and Pharmacoeconomics Opportunities*. Invited lecturer at Sullivan

- University. Louisville, Kentucky, June 5, 2018.
12. **Mattingly J.** *Emotional Intelligence*. American Pharmacists Association Annual Meeting. San Francisco, California. March 25, 2017.
 13. **Mattingly J.** *Mobile Health and Remote Monitoring in the Pharmacy*. Maryland Pharmacists Association Midyear Meeting. Columbia, Maryland. February 12, 2017.
 14. Mackenzie A, Pier K, **Mattingly J.** *Obesity Treatments*. MidAtlantic Business Group on Health Obesity Forum. Baltimore, Maryland. June 9, 2016.
 15. **Mattingly J.** *Mobile Health and Remote Monitoring in the Pharmacy*. Kentucky Pharmacists Association Annual Meeting. Louisville, Kentucky. June 4, 2016.
 16. **Mattingly J.** *Modeling Medication Safety: A beginner's guide to a pharmacoeconomic approach to evaluating medication safety strategies*. Washington Metropolitan Society of Health-System Pharmacists Spring 2016 Pharmacy Meeting. Rockville, Maryland. May 15, 2016.
 17. **Mattingly J.** *New Practitioner Network Workshop Practical Financial Planning Strategies*. American Pharmacists Association Annual Meeting. Baltimore, Maryland. March 7, 2016.
 18. **Mattingly J.** *Specialty Pharmacy: A multi-stakeholder forum*. MidAtlantic Business Group on Health. Baltimore, Maryland. October 13, 2015.
 19. **Mattingly J.** *Mobile Health and Remote Monitoring in the Pharmacy*. National Community Pharmacists Association Annual Convention. National Harbor, Maryland. October 10, 2015.
 20. Ashby E, **Mattingly J.** *Practical Tips on Financial Planning*. 22nd Annual Mid-Atlantic ASCP Conference. Gettysburg, Pennsylvania. August 8, 2015.
 21. **Mattingly J.** *Financial & Ethical Implications of New HCV Therapy*. Maryland Society of Health-System Pharmacists Spring Seminar. Baltimore, Maryland. May 2015.
 22. **Mattingly J.** *Dollars and Per-cents: Understanding Pharmacy Finance*. Kappa Psi Pharmaceutical Fraternity Spring Province Meeting. Baltimore, Maryland. April 2015.
 23. **Mattingly J.** *Navigating Recruitment Forums and Negotiation Strategies*. University of Maryland Residency Program Professional Development Series. Baltimore, Maryland. January 2015.
 24. **Mattingly J.** *National Community Pharmacists Association Business Plan Workshops I & II*. University of Maryland NCPA Chapter. Baltimore, Maryland. January 2015.
 25. Winslow C, **Mattingly J.** *Real World Financial Planning*. American Pharmacists Association ASP/NPN Webinar Series. Online. July 2014.
 26. **Mattingly J.** *Friend Request: E-professionalism and social media in the pharmacy*. American Pharmacists Association Annual Meeting. Los Angeles, California. March 2013.
 27. **Mattingly J,** Cain J. *Pharmacists on Facebook: Issues addressing the impact of online social media on corporate pharmacy and the profession*. The Kroger Company Mid South Division Pharmacy Meeting. New Albany, Indiana. August 2010.
 28. Cain J, **Mattingly J.** *Social Media and Pharmacy: E-professionalism, Impression Management, & Opportunities*. University of Charleston School of Pharmacy. Charleston, West Virginia. March 2010.
 29. Cain J, Dabestani A, Dotter E, **Mattingly J.** *E-Professionalism: The emerging impact of social media on pharmacy professionals*. American Society of Health-System Pharmacy Midyear Clinical Meeting. December 2009.
 30. **Mattingly J.** *Health Literacy: Improving your patient's understanding*. Communications and Public Education Working Group (CPEWG) within the British Columbia Ministry of Health. Victoria, British Columbia, Canada. May 2008.

CONSULTING & EXPERT WITNESS WORK

1. *Assistant Secretary for Planning and Evaluation (ASPE) / RAND Corporation*. Invited to serve on a Technical Advisory Panel (TEP) of US policy and economic experts to advise ASPE on research design specific to evaluating the outcomes of the Inflation Reduction Act of 2022. 2024.
2. *Pharmaceutical Research and Manufacturers of America (PhRMA)*. Multiple projects. Ongoing.
3. *Pharmaceutical Care Management Association (PCMA)*. Pharmacy closure analysis. 2023-2024.
4. *Academy of Managed Care Pharmacy*. Lead for the new "Managed Care Pharmacy Emerging Trends Initiative." This project will capture national trends in managed care pharmacy practice. 2024.
5. *Arnold Foundation*. Work for the Johns Hopkins Drug Affordability Center on drug pricing policy. Ongoing.
6. *Ferrari Partners, PLLC*. Drug pricing and workers compensation expert witness. Ongoing.

7. *Vanderbilt University*. Work on drug cost conversations between patients and providers. 2022.
8. *Neal Harwell Attorneys at Law*. Expert witness for pharmaceutical supply chain lawsuit. 2022.
9. *Massachusetts Health Policy Commission*. Drug pricing. State and Paid. Work published within the Prescription Drug Coupon Study, July 2020. Available at: <https://www.mass.gov/doc/prescription-drug-coupon-study/download>
10. *National Health Council*. Patient engagement research. 2020.
11. *Cancer Support Community*. Health economic resource development. 2020.
12. *Asthma and Allergy Foundation of America*. Value assessment framework. 2019.
13. *G&W Laboratories*. Therapeutic exchange application development. 2019.
14. *American Pharmacists Association*. Educational program development. 2019.
15. *Bristol-Myers Squibb*. Expert speaker. 2018.
16. *Paratek Pharmaceuticals*. Health Economics and Outcomes Research Advisory Board. 2017.
17. *Summit Therapeutics*. Health Technology Assessment Advisory Board. February 2017.
18. *Resnick, Chodorow, and Associates, LLC*. Expert for formulary dossier preparation for a national patient assistance network. December 2016.
19. *Kelly IP, LLP*. Expert witness consulting regarding pharmaceutical intellectual property brand value of formulation. October 2015.
20. *KesslerTopazMeltzerCheck, LLP*. Expert witness consulting regarding a national pharmacy chain case. August 2015.
21. *Pharmacy Quality Alliance Stakeholder Advisory Panel C*. Assist with the development and measure concepts for PQA initiatives. April 2015 – 2016.
22. *Gerson Lehrman Group*. April 2014 – 2018.

MEDIA COVERAGE

1. *Bloomberg Law*. Pharmacies, Drugmakers on Edge for Rollout of US Drug Price Cuts. August 29, 2024. Available at: <https://news.bloomberglaw.com/health-law-and-business/pharmacies-drugmakers-on-edge-for-rollout-of-us-drug-price-cuts>
2. *Insurance Journal*. What you need to know about 2024 federal prescription reform. Featured guest for a series developed by PCF Insurance Services. August 2, 2024. Available at: <https://www.insurancejournal.com/blogs/pcf/2024/08/02/784246.htm>
3. *On Point (Podcast by WBUR)*. Featured guest on a podcast episode examining Amazon's entry into the pharmacy industry. February 17, 2023 Available: <https://www.wbur.org/onpoint/2023/02/17/what-amazons-push-into-health-care-means-for-patients>
4. *Bloomberg Law*. Quoted in article on COVID-19 prescriber rules and "test to treat" initiative. March 2022. Available: <https://news.bloomberglaw.com/health-law-and-business/covid-pill-prescriber-rules-limit-reach-of-test-to-treat-plan>
5. *Bloomberg Law*. Quoted in article on COVID-19 medication dispensing costs for pharmacies. January 2022. Available: <https://news.bloomberglaw.com/health-law-and-business/covid-pill-dispensing-costs-push-pharmacies-to-call-on-medicare>
6. *Bloomberg Law*. Quoted in article on 340B discount program legal battles. January 2022. Available: <https://news.bloomberglaw.com/health-law-and-business/pharma-chips-away-at-discount-drugs-while-battling-hhs-in-court>
7. *WUFT News*. Quoted in article covering rural Florida pharmacy business issues worsed by COVID-19 pandemic. December 2021. Available: <https://www.wuft.org/news/2021/12/17/rural-florida-pharmacies-struggling-worsened-by-pandemic/>
8. *Fortune*. Quoted in article regarding GoodRx business model. April 2021. National. Available: <https://fortune.com/2021/04/29/goodrx-prescription-drug-costs-pbms/>
9. *Los Angeles Times*. Quoted in article regarding recent drug pricing policy changes proposed through executive order. August 2020. National. Available: <https://www.latimes.com/business/story/2020-08-27/david-lazarus-prescription-drug-prices>
10. *Your Financial Pharmacist Podcast*. Guest featured on the topic of student loan interest rates and proposals to cancel student debt. 2019. Available: <https://yourfinancialpharmacist.com/yfp-125-why-lowering-interest-rates-for-student-loans-is-an-alternative-to-debt-cancellation/>
11. *Talk to Your Pharmacist Podcast*. Guest to discuss pursuing a PhD after the PharmD. 2019. Available: <https://soundcloud.com/pharmacyadvisorygroup/ttyp-joeey-mattingly-062219>

12. *Washington Post*. Quoted in article regarding business strategy and the price of Daraprim® post-Shkreli. 2018. Available: <https://www.washingtonpost.com/>
13. *American Pharmacist Association Press Release*. Announcement regarding election to serve a 3-year term for the American Pharmacists Association as Speaker of the House of Delegates and Trustee. 2018. Available: <https://www.pharmacist.com/press-release/joey-mattingly-elected-2018-2019-apha-hod-speaker-elect>
14. *WBAL*. Interviewed to discuss pharmaceutical supply chain challenges post-Hurricane Maria. 2017. Available: <https://www.wbaltv.com/article/puerto-ricos-prescription-drug-industry-hindered-by-hurricane/12840780>
15. *MD Magazine*. Research on the lack of patient engagement in economic analyses for Hepatitis C featured following publication in *Hepatology*. 2017. Available: <https://www.mdmag.com/medical-news/analysis-patient-voice-lacking-in-hcv-costeffectiveness-research>
16. *MD Magazine*. Research on the cost-effectiveness of new Hepatitis C treatments featured. 2017. Available: <https://www.mdmag.com/medical-news/what-is-the-most-costeffective-hcv-drug-regimen>
17. *Your Financial Pharmacist Podcast*. Guest featured on the topic of rising student debt following research published on graduating student net income. 2017. Available: <https://yourfinancialpharmacist.com/the-impact-of-rising-student-debt-on-a-pharmacists-income/>
18. *Drug Topics*. Quoted in article on mobile health in pharmacy practice. October 2015. National.
19. *Huffington Post*. Quoted in article regarding Turing Pharmaceuticals' controversial drug price increase. September 2015. National. Available at: https://www.huffpost.com/entry/daraprim-price-turing-shkreli_n_560063cee4b00310edf82060
20. *Baltimore Fox 45*. Interviewed by local news team following Turing Pharmaceuticals' controversial drug price increase. September 2015. Local.
21. *Attn.com*. Quoted in article on cough & cold medications. June 2015. National.

BOOK CHAPTERS

1. **Mattingly II TJ**. Pharmacoeconomics. In: Remington-The Science and Practice of Pharmacy. 23rd ed. London, UK: Pharmaceutical Press;in production.
2. **Piascik P, Mattingly TJ**. Contraceptives. In: Smith KM, Riche D, Henyan N, eds. *Clinical Drug Data*. 11th ed. New York, NY: McGraw Hill; 2010:806-25.

OTHER SELECTED PUBLICATIONS (Not Peer-Reviewed)

1. **Mattingly J**. A Prescription for More Affordable Pharmacy Education. *University of Utah Health: Good Notes Blog*. October 4, 2023. Available at: <https://uofuhealth.utah.edu/notes/2024/03/affordable-pharmacy-education-first-year-free>
2. **Mattingly J**. Nuanced Approach to Pharmacoeconomics Research. *University of Utah Health: Good Notes Blog*. October 4, 2023. Available at: <https://uofuhealth.utah.edu/notes/2023/10/pharmacoeconomics-research>
3. **Wosinska ME, Mattingly II TJ, Conti RM**. A Framework For Prioritizing Pharmaceutical Supply Chain Interventions. September 13, 2023. DOI: 10.1377/forefront.20230912.938681
4. **Mattingly II TJ, Bai G**. Reforming Pharmacy Direct And Indirect Remuneration In The Medicare Part D Program. *Health Affairs Forefront*. July 19, 2021. DOI: 10.1377/forefront.20210714.70749
5. **Mattingly II TJ, Kennedy, Kefauver, And Castro**: A Historical Lesson On The Politics Of Drug Pricing Reform. *Health Affairs Forefront*. November 1, 2021. DOI: 10.1377/forefront.20211029.33540
6. McQueen RB, **Mattingly J**. Using PCORI to advance patient-centered values. *Fierce Healthcare*. November 6, 2019.
7. **Mattingly II TJ, Slejko JF, Perfetto EM, dosReis SC**. Putting our guard down: Engaging multiple stakeholders to define value in healthcare. *Health Affairs Blog*. January 28, 2019.
8. **Mattingly II TJ**. Pharmacoeconomics Refresher: The CVS \$100k/QALY announcement (Parts 1-3). *AJMC* special contributor series. 2018. Available: <https://www.ajmc.com/contributor/joey-mattingly>
9. **Mattingly II TJ, Gaballah M***. 340B Overview: The Evolution of Drug Price Discounts in the United States. *Pharmacy Times Continuing Education*. November 10, 2016.

10. **Mattingly II TJ**, Miller C. The use of over-the-counter oral rehydration salt (ORS) solutions. *Kentucky Pharmacist*. 2015 (May/June);10(3):14-19.
11. **Mattingly J**. Social Networking: Issues addressing the impact of online social media on pharmacy organizations and the profession. *Indiana Pharmacist*. 2013 (March).
12. **Mattingly J**. Understanding Drug Pricing. *US Pharmacist (Generic Drug Supplement)*; 2012:72.
13. **Mattingly J**. Will FTC revisit PBM ownership of mail-order pharmacies post-merger? *Pharmacy Today*. 2012.
14. **Mattingly TJ**, Yusuf JW, Fink JL. Turning that great idea into a thriving business. *Pharmacy Times* (online edition). 2009 (February).

JOURNAL SERVICE (Editorial Appointments)

Associate Editor, <i>Value in Health</i>	June 2024 – Present
Editorial Board Member, <i>Pharmacoeconomics – Open</i>	November 2018 – Present
Editorial Board Member, <i>American Journal of Pharmaceutical Education</i>	July 2017 – Present
Editorial Board Member, <i>Pharmacy Today</i>	March 2009 – March 2012
Editorial Board Member, <i>Student Pharmacist Magazine</i>	March 2007 – March 2008

GRANT REVIEW PANEL SERVICE

Reviewer, NIA Special Emphasis Panel U54 – Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)	October 2023
Reviewer, NIMHD Special Emphasis Panel ZMD1 (A1) R – Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)	July 2023
Reviewer, NIMHD Loan Repayment Applications ZMD1 KNL NOT-OD-22-150 Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR).	January 2023
Reviewer, NIMHD Special Emphasis Panel ZMD1 (A1) R – Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)	July 2022
Reviewer, AHRQ Special Emphasis Panel ZHS1 HSR-X (01) – Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)	August 2020

REVIEWER FOR THE FOLLOWING JOURNALS

<i>Journal of the American Medical Association</i>	<i>American Journal of Pharmaceutical Education</i>
<i>Annals of Internal Medicine</i>	<i>Pharmacotherapy</i>
<i>Value in Health</i>	<i>Journal of Managed Care & Specialty Pharmacy</i>
<i>Health Affairs</i>	<i>Health Affairs Scholar</i>
<i>Pharmacoeconomics</i>	<i>American Journal of Managed Care Pharmacy</i>
<i>Applied Health Economics and Health Policy</i>	<i>Pharmacogenomics</i>
<i>BMJ Open</i>	<i>Journal of the American Pharmacist Association</i>
<i>BMJ Global Health</i>	<i>NEJM Catalyst</i>
<i>PLOS One</i>	<i>Clinical Drug Investigation</i>
<i>Clinical & Experimental Allergy</i>	<i>Annals of Allergy, Asthma & Immunology</i>
<i>Int J of Health Policy and Management</i>	<i>INNOVATIONS in pharmacy</i>
<i>J of Health Care for the Poor and Underserved</i>	<i>Currents in Pharmacy Teaching and Learning</i>

COURSES TAUGHT

Course name	Course Prefix and Number	Credits	Students	Type of students	My Role	Year(s) Taught
University of Utah College of Pharmacy (2022 – Present)						
Drug Literature and Evaluation II	PHARM 6241	3	50	PharmD	Course Manager	2024 – Present
Managed Care Elective	PHARM 7552	2	20	PharmD	Course Manager	2023 – Present
Healthcare Policy	PHARM	3	50	PharmD	Instructor	2023 – Present
University of Maryland School of Pharmacy (2014 – 2022)						
Pharmacy Practice Management	PHAR 562	3	160	PharmD	Course Manager	2014 – 2022
Abilities Lab 6	PHAR 567	2	160	PharmD	Course Manager	2015 – 2019
Abilities Lab 1	PHAR 505	2	160	PharmD	Instructor	2014 – 2018
Professionalism & Ethics in Pharm Pract	PHAR 507	2	160	PharmD	Instructor	2015 – 2022
NCPA Business Plan Competition	PHMY 5002	2	20	PharmD	Course Manager	2016 – 2019
Effective Leadership and Advocacy	PHMY 598	2	60	PharmD	Course Manager	2016 – 2022
Applied Science & Therapeutics 4	PHAR 5004	2	160	PharmD	Instructor	2017
Health Policy and Systems	PHAR 5010	3	160	PharmD	Instructor	2017 – 2019
Comparative Effectiveness Research and Patient-Centered Outcomes Research	PHSR 705	2	6	PhD	Course Manager	2019 – 2022
Cancer Epidemiology	PREV 701	3	10	MD, MS, PhD	Instructor	2020 – 2022
Introduction to Clinical and Translational Research	N/A	1	120	Grad	Instructor	2019 – 2021

MENTORSHIP (Graduate Students, Residents and/or Postdoctoral Fellows)

Student, Resident, or Fellow Name	Training Type	Years Under Supervision	Project Title
University of Utah			
K. Ben-Umeh, PhD student	Advisor	2023 – Present	Primary advisor
Elvis Duru, PhD Student	Advisor	2023 – Present	Primary advisor
University of Maryland			
Adrienne Kowcz, PharmD	Research Advisor	2014 – 2015	“Patient satisfaction using a bedside delivery service.”
Maggie Miklich, PharmD	Research Advisor	2014 – 2015	“Expert panel on professional engagement.”
Maggie Miklich, PharmD	Research Advisor	2015 – 2016	“Treatment interruptions in Hepatitis C therapy.”
Hanna Park, PharmD	Research Advisor	2015 – 2016	“Capturing the Value of Clinical Pharmacy Services.”
Timothy Wu, PharmD	Research Advisor	2016 – 2017	“Cost-benefit analysis of bedside delivery services.”
Kathy Tang, PharmD	Research Advisor	2016 – 2017	“Cost-minimization analysis of sotalol.”
M. Abdelwadoud, MD, DrPH	Co-Advisor	2018 – 2021	Multiple projects under 2-year fellowship
Erin Roth, PhD	Co-Advisor	2020 – 2021	Multiple projects under 2-year fellowship
Mary K. Huffman, PhD	Co-Advisor	2021 – 2022	Multiple projects under 2-year fellowship
Jennifer Choi, PhD	Advisor	2022 – 2023	Multiple projects under 1-year fellowship
Bansri Desai	Research Advisor	2020 – 2023	PhD Dissertation Committee member

MENTORSHIP (PharmD Students and Pharmacy Organizations)

Name or group	Your Role	Years Under Supervision
University of Utah		
Academy of Managed Care Pharmacy – Utah Chapter	Advisor	2022 – Present
Jackson Johnson (PharmD Student, Class of 2027)	Advisor	2023 – Present
Katie Compagni (PharmD Student, Class of 2027)	Advisor	2023 – Present
Kaitlin Gilmore (PharmD Student, Class of 2027)	Advisor	2023 – Present
Joseph Simpson (PharmD Student, Class of 2026)	Advisor	2023 – Present
Katelyn Smith (PharmD Student, Class of 2026)	Advisor	2023 – Present
University of Maryland		
Kappa Psi Pharmaceutical Fraternity (Maryland)	Advisor	2014 – 2018
National Community Pharmacists Association (Maryland)	Advisor	2015 – 2022

Phi Lambda Sigma	Invited Speaker	2014 – 2019
A Bridge to Academic Excellence	Invited Speaker	2015 – 2016
Class of 2023 Group advisor (University of Maryland)	Advisor	2019 – 2023
Class of 2019 Group advisor (University of Maryland)	Advisor	2015 – 2019
Christopher St. Clair (PharmD Student)	Advisor	2014 – 2016
Jason Keung (PharmD Student)	Advisor	2014 – 2016
Anh Nguyen (PharmD Student)	Advisor	2014 – 2016
Edward Neuberger (PharmD Student)	Advisor	2014 – 2017
Wilhelmia Lord-Adem (PharmD Student)	Advisor	2014 – 2016

SERVICE (Department, School, and University)

University of Utah College of Pharmacy

- Vice President for Research's 1U4U Seed Grant Committee (University) 2024 – Present
- Population Health Steering Committee (University) 2024 – Present
- Research & Science Advisors Committee-ad hoc, CTSA (University) 2024 – Present
- Chair, Tenure-Track Faculty Search (Department) 2023 – 2024
- Assessment Committee (School) 2023 – Present
- Research Strategy Committee (School) 2023 – Present
- Affordable Pharmacy Education Initiative, Task Force Chair (School) 2023 – 2024
- Department Leadership Team, Member (Department) 2022 – Present
- Graduate Program Committee, Member (Department) 2022 – Present

University of Maryland School of Pharmacy

- Curriculum Committee, Ex-Officio as Vice-Chair (School) 2020 – 2022
- Department Curriculum Committee, Chair (Department) 2020 – 2022
- Department Leadership Team, Member (Department) 2020 – 2022
- Pharmapreneurship Task Force Member (School – ad hoc) 2018 – 2022
- Admission Committee Member (School) 2017 – 2019
- Curriculum Committee Member (School) 2014 – 2016
 - Committee Vice-Chair 2015 – 2016
- Faculty Search Committee, Assistant Professor of Pharmacoeconomics 2015 – 2016
- Faculty Search Committee, multiple positions for pharmacy practice 2014 – 2015
- Student Affairs Committee Member (School) 2014 – 2015
- Strategic Planning – Entrepreneurship Subcommittee Member (Department) 2014 – 2016
- Outpatient Services Workgroup Member (School – ad hoc) 2014 – 2016
- Technician Training – Community Advisory Board Member (School – ad hoc) 2014 – 2016
- Abilities Lab Faculty Workgroup Member (Department – ad hoc) 2014 – 2016

University of Kentucky College of Pharmacy

- Development Committee Member (School) 2012 – 2014
- Curriculum Committee Member (School) 2011 – 2012
- College Admissions Committee Member (School) 2005 – 2009
- College Senator, Student Senate (University) 2006 – 2008
- Student Advisory Council Chair (School) 2006 – 2008

SERVICE (Leadership in Scientific, Professional and Scholarly Organizations)

National Association of Insurance Commissioners (NAIC)

- Research Fellow 2023 – Present

Patient-Centered Outcomes Research Institute (PCORI)

- Advisory Panel on Clinical Effectiveness and Decision Science (CEDS) 2020 – 2023

Maryland Department of Health Prescription Drug Monitoring Program

- Advisory Board Member 2020 – 2022

American Pharmacists Association

- House Rules Review Committee, Member (National) 2024 – Present
- Speaker of the House of Delegates & Trustee (National) 2019 – 2021
- Speaker-elect of the House of Delegates (National) 2018 – 2019
- APhA New Business Review Committee (National) 2017 – 2018
- APhA Political Action Committee, Board of Governors (National) 2016 – 2018
- APhA Media Advisor (National) 2016 – 2018
- APhA-APRS Engage Community Moderator (National) 2015 – 2018
- APhA-APRS Communications Standing Committee (National) 2014 – 2015
- Policy Committee Member (National) 2013 – 2014
- New Practitioner Network Standing Committee (National) 2012 – 2013
- APhA-ASP Speaker of the House (National) 2008 – 2009
- Political Action Committee Board of Governors Member (National) 2008 – 2009
- Foundation Advisory Committee Member (National) 2008 – 2009
- Vice Chair, APhA-ASP Standing Committee on Communications (National) 2007 – 2008
- Chapter President, University of Kentucky (Local) 2007 – 2008

American Association of Colleges of Pharmacy

- Council of Faculty – Faculty Affairs Committee (National) 2020 – Present
- PharmGrad Advisory Committee Member (National) 2018 – 2019
- Council of Faculty – Faculty Affairs Committee (National) 2017 – 2018

American Society of Health-Systems Pharmacists

- Section Advisory Group on Management of Pharmacy Enterprise (National) 2017 – 2018

Cancer Support Community Research and Training Institute

- Board Member (National) 2020 – Present

Pharmacy Quality Alliance (National)

- Stakeholder Advisory Panel Member 2015

American Society of Consultant Pharmacists

- Maryland Chapter, Board of Directors Member (State) 2014 – 2017
- Kentucky Chapter, Board of Directors Member (State) 2012 – 2014

Kentucky Pharmacists Association (State)

- Board of Directors Member 2009 – 2012
- Organizational Affairs Committee Chair 2011 – 2012
- Policy Review Committee Member 2011 – 2012
- Parliamentarian 2011 – 2012
- Louisville Health Information Exchange Committee Member 2010 – 2012
- Speaker of the House of Delegates 2011 – 2012

Maryland Pharmacists Association (State)

- Communications Committee Member 2014 – 2016
- Resolutions Committee Member 2014 – 2016

Kappa Psi Pharmaceutical Fraternity

- Chair, Leadership Symposium Task Force (National) 2017 – 2018
- Chair, Constitutional Review Task Force (National) 2016 – 2017

- Assistant Supervisor, Atlantic Province (Regional) 2015 – 2017
- Proxy Voting Task Force Chair (National) 2013 – 2015
- Faculty Advisor, Sigma Chapter (School) 2014 – 2018
- Parliamentarian (National) 2011 – 2012
- Maryland Graduate Chapter Member (State) 2014 – 2022
- Kentucky Graduate Chapter Member (State) 2009 – Present
- Upsilon Chapter Member (School) 2006 – 2009

Phi Lambda Sigma Pharmacy Leadership Society

- Speaker of the House of Delegates (National) 2007 – 2008
- Chi Chapter Member (School) 2006 – 2009

Jefferson County Academy of Pharmacy

- President (Local) 2010 – 2012
- Vice President (Local) 2009 – 2010

SERVICE (Memberships)

American Pharmacists Association (APhA)	Phi Lambda Sigma
American Association of Colleges of Pharmacy (AACP)	Rho Chi
AcademyHealth	Kappa Psi
Academy of Managed Care Pharmacy (AMCP)	Maryland Pharmacists Association
Infectious Diseases Society of America (IDSA)	University Fellow, University of Kentucky
Society for Infectious Diseases Pharmacists (SIDP)	Maryland Responds Medical Reserve Corps
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)	

CERTIFICATIONS AND LICENSURE

Pharmacist License, Kentucky	License Number: 014493
Pharmacist License, Indiana	License Number: 26024802A
Pharmacist License, Maryland	License Number: 22832
National Provider Identifier Number	1871887380
Pharmacoeconomic Modeling – Advanced Course	Certificate of Completion
Pharmacogenomics Course for Pharmacists	Certificate of Completion